Results 11 to 20 of about 182,230 (304)

Clinicopathological Characteristics and Outcomes of Lupus Nephritis Patients With Thrombocytopenia: A Single‐Center Retrospective Study [PDF]

Immunity, Inflammation and Disease
Objectives The objective of this study is to analyze and summarize the clinical characteristics and prognosis of lupus nephritis (LN) patients with thrombocytopenia and to improve the cognition of the disease.
Hui Diao, Yuting Fan, Di Kang, Zhiqing Chen, Yuewen Lu, Xiamin Huang, Xi Xia, Wei Chen   +7 more
doaj   +2 more sources

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer

Annals of Gastroenterological Surgery, Volume 7, Issue 1, Page 81-90, January 2023., 2023
XELOXIRI neoadjuvant chemotherapy appears to be feasible and efficacious for patients with LARC. Although neoadjuvant XELOXIRI alone did not yield our expected pCR rate, the local recurrence rate, 3‐year DFS and measures of safety met current standards.
Chu Matsuda, Toshihiro Kudo, Yoshihiro Morimoto, Yoshinori Kagawa, Mitsuyoshi Tei, Yoshihito Ide, Norikatsu Miyoshi, Hidekazu Takahashi, Mamoru Uemura, Ichiro Takemasa, Taroh Satoh, Tsunekazu Mizushima, Kohei Murata, Yuichiro Doki, Hidetoshi Eguchi, Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MSCSGO)   +16 more
wiley   +1 more source

Cost‐effectiveness of second‐line therapies in adults with chronic immune thrombocytopenia

American Journal of Hematology, Volume 98, Issue 1, Page 122-130, January 2023., 2023
Abstract Major options for second‐line therapy in adults with chronic immune thrombocytopenia (ITP) include splenectomy, rituximab, and thrombopoietin receptor agonists (TRAs). The American Society of Hematology guidelines recommend rituximab over splenectomy, TRAs over rituximab, and splenectomy or TRAs while noting a lack of evidence on the cost ...
George Goshua, Pranay Sinha, Natalia Kunst, Lauren Pischel, Alfred Ian Lee, Adam Cuker   +5 more
wiley   +1 more source

Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study

American Journal of Hematology, Volume 98, Issue 1, Page 11-22, January 2023., 2023
Treatment process evolution. *The target TNC for BMH was ≥6 × 108/kg per patient. The Group B1 patient received lovo‐cel produced using both the original and refined manufacturing process, and the Group B2 patient received lovo‐cel produced using only the refined manufacturing process.
Julie Kanter, Alexis A. Thompson, Francis J. Pierciey Jr, Matthew Hsieh, Naoya Uchida, Philippe Leboulch, Manfred Schmidt, Melissa Bonner, Ruiting Guo, Alex Miller, Jean‐Antoine Ribeil, David Davidson, Mohammed Asmal, Mark C. Walters, John F. Tisdale   +14 more
wiley   +1 more source

Romiplostim use in pregnant women with immune thrombocytopenia

American Journal of Hematology, Volume 98, Issue 1, Page 31-40, January 2023., 2023
Abstract Treatment for immune thrombocytopenia (ITP) in pregnancy is hampered by the lack of fetal safety evidence of maternally‐administered medications. The Pregnancy Surveillance Program (PSP) collected patient information from 2017–2020 for pregnancy, birth outcomes, and adverse events (AEs) for 186 women exposed to romiplostim from 20 days before ...
James B. Bussel, Nichola Cooper, Tatiana Lawrence, Marc Michel, Emilie Vander Haar, Kejia Wang, Hongmei Wang, Hossam Saad   +7 more
wiley   +1 more source

Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management

American Journal of Hematology, Volume 98, Issue 1, Page 193-209, January 2023., 2023
Abstract Disease Overview Cutaneous T‐cell lymphomas are a heterogenous group of T‐cell neoplasms involving the skin, the majority of which may be classified as Mycosis Fungoides (MF) or Sézary Syndrome (SS). Diagnosis The diagnosis of MF or SS requires the integration of clinical and histopathologic data.
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox   +2 more
wiley   +1 more source

A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes

American Journal of Hematology, Volume 98, Issue 2, Page 272-281, February 2023., 2023
Abstract Patients with relapsed/refractory (R/R) higher‐risk myelodysplastic syndromes (MDS) have a dismal median overall survival (OS) after failing hypomethylating agent (HMA) treatment. There is no standard of care for patients after HMA therapy failure; hence, there is a critical need for effective therapeutic strategies.
Amer M. Zeidan, Uma Borate, Daniel A. Pollyea, Andrew M. Brunner, Fernando Roncolato, Jacqueline S. Garcia, Robin Filshie, Olatoyosi Odenike, Anne Marie Watson, Ravitharan Krishnadasan, Ashish Bajel, Kiran Naqvi, Jiuhong Zha, Wei‐Han Cheng, Ying Zhou, David Hoffman, Jason G. Harb, Jalaja Potluri, Guillermo Garcia‐Manero   +18 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia

American Journal of Hematology, Volume 98, Issue 2, Page 338-347, February 2023., 2023
Abstract Bruton tyrosine kinase (BTK) inhibitors have taken a central role in the management of patients with Waldenström macroglobulinemia and are the only agents approved by the Food and Drug Administration (FDA) to treat these patients. Although associated with high rates of durable responses, unmet needs with BTK inhibitor therapy include ...
Jorge J. Castillo, Christian Buske, Judith Trotman, Shayna Sarosiek, Steven P. Treon   +4 more
wiley   +1 more source

Thrombocytopenia in pregnancy [PDF]

Hematology, 2017
Abstract Thrombocytopenia develops in 5% to 10% of women during pregnancy or in the immediate postpartum period. A low platelet count is often an incidental feature, but it might also provide a biomarker of a coexisting systemic or gestational disorder and a potential reason for a maternal intervention or treatment that might pose harm ...
Douglas B. Cines, Lisa D. Levine
openaire   +6 more sources

Risk Factors of Thrombocytopenia After Cardiac Surgery with Cardiopulmonary Bypass

Brazilian Journal of Cardiovascular Surgery, 2022
Introduction: Postoperative thrombocytopenia is common in cardiac surgery with cardiopulmonary bypass, and its risk factors are unclear. Methods: This retrospective study enrolled 3,175 adult patients undergoing valve surgeries with cardiopulmonary ...
Shujie Yan, Sizhe Gao, Song Lou, Qiaoni Zhang, Yuefu Wang, Bingyang Ji   +5 more
doaj   +1 more source